At the appropriate pages, prior to the text on each page, please delete the header that reads "WO 00/30654 PCT/GB99/03952" if necessary.

In the Claims:

After entry into the U.S. national stage, and assurance of a U.S. filing date, please revise the claims from the enclosed published PCT application as follows.

Please amend published PCT claims 1, 6, 8, 10, 11, 14-30 and 32-34, so that the rewritten claims read as follows:

a3

1. (Amended) A therapeutic combination product for use in the prevention and/or treatment of asthma comprising (a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL composition including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature and (b) an antiasthma drug, wherein ingredients (a) and (b) are provided in a form for administration together or separately.

a4

6. (Amended) A combination product as claimed in claim 2, in which the medicament (a) comprises a phosphatidyl glycerol.

a5

8. (Amended) A combination product as claimed in claim 2, in which the medicament (a) comprises one or more compounds selected from the group consisting of diacyl phosphatidyl cholines.

a6

10. (Amended) A combination product as claimed in claim 2, in which the medicament (a) is in micronised form.

11. (Amended) A combination product as claimed in claim 2, in which said medicament (a) has a median particle size not exceeding 10μm.

14. (Amended) A combination product as claimed in claim 2, in which the antiasthma drug comprises one or more respiratory drugs selected from the group consisting of β_2-agonists, steroids, cromones, antimuscarinic drugs and leukotriene receptor antagonists.

15. (Amended) A combination product as claimed in claim 14, which comprises one or more of said antiasthma drugs in an amount of up to 10 parts by weight per hundred parts by weight of said first and second components of medicament (a) in combination.

16. (Amended) A combination product as claimed in claim 15, which comprises one or more of said respiratory drugs in an amount of up to one part by weight per hundred parts by weight of said first and second components of medicament (a) in combination.

17. (Amended) A combination product as claimed in claim 14, in which ingredient (b) comprises a β_2-agonist.

18. (Amended) A combination product as claimed in claim 14, in which ingredient (b) comprises a steroid.

19. (Amended) A combination product as claimed in claim 14, in which ingredient (b) comprises a cromone.

20. (Amended) A combination product as claimed in claim 14, in which ingredient (b) comprises a leukotriene receptor antagonist.

21. (Amended) A combination product as claimed in claim 14, in which ingredient (b) comprises an antimuscarinic drug.

22. (Amended) A combination product as claimed in claim 2, in which at least ingredient (a) is arranged to be delivered to a patient in the form of at least one individual inhalable dose, the individual dose or each individual dose comprising said ingredient (a) in an amount of at least 10mg.

23. (Amended) A combination product as claimed in claim 22, in which the individual dose or each individual dose comprises said first and second components in a combined amount of at least 25mg.

24. (Amended) A combination product as claimed in claim 23, in which the individual dose or each individual dose comprises said ingredient (a) in a combined amount of at least 40mg.

25. (Amended) A combination product as claimed in claim 22, in which at least ingredient (a) is arranged for sequential delivery of a multiplicity of inhalable doses.

26. (Amended) A combination product as claimed in claim 1 or claim 2, in which the antiasthma drug is arranged for delivery in admixture with ingredient (a).

27. (Amended) A combination product as claimed in claim 1 or claim 2, in which the antiasthma drug is arranged for delivery separately from, and simultaneously or sequentially with, ingredient (a).

28. (Amended) A pack for use as part of a combination product according to claim 1 or claim 2, said pack including a delivery device for delivery of ingredient (a) to a patient and further comprising instructions to use said delivery device in a method of treatment including the separate simultaneous or sequential administration of an antiasthma drug.

29. (Amended) A method of prevention and/or treatment of asthma, comprising administering to a patient at least one dose of a combination product as defined in claim 1 or claim 2.

30. (Amended) A delivery device for administering to a patient by inhalation a medicament for the prevention and/or treatment of asthma, the delivery device containing a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL composition including a component which enhances the spreading of the medicament, the delivery device being arranged for delivery of at least one individual dose of the SAPL composition in an amount of at least 10mg.

32. (Amended) A delivery device as claimed in claim 30, in which the medicament is as defined in claim 2.

33. (Amended) A delivery device as claimed in claim 30 or 31, which further includes means for dispensing an inhalable dose of an antiasthma drug.

34. (Amended) A medicament for use in the control of asthma, comprising (a) a surface active phospholipid (SAPL) composition in finely divided form conjointly with (b) an antiasthma drug.

REMARKS

I. Nationalization

This application represents the U.S. national stage of International Patent Application PCT/GB99/03952, filed November 26, 1999, which claims priority to British Patent Application 9912639.3, filed 28 May, 1999 and to International Patent Application PCT/GB98/03543, filed November 26, 1998.

As the text of the International Application was transmitted by the International Bureau, an additional copy is not required to satisfy 35 U.S.C. § 371(c)(2). Nonetheless, for the Examiner's convenience, a copy of international application PCT/GB99/03952 is enclosed in the form of the published PCT Application WO 00/30654.

Although claim amendments were made during PCT examination, for the convenience of the U.S. examiner, the unamended claims of the published PCT Application form the initial basis of the present claims and any amendments thereto are clearly shown in the attached exhibits.